Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.53 USD | -1.37% | -1.28% | -29.39% |
Apr. 15 | Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer | CI |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Business Summary
Number of employees: 526
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Genome Editing-based Therapies
100.0
%
| 52 | 100.0 % | 36 | 100.0 % | -30.40% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 52 | 100.0 % | 36 | 100.0 % | -30.40% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
John Leonard
CEO | Chief Executive Officer | 66 | 14-06-30 |
Glenn Goddard
DFI | Director of Finance/CFO | 53 | 18-10-28 |
Eliana Clark
CTO | Chief Tech/Sci/R&D Officer | 67 | - |
Chief Tech/Sci/R&D Officer | 63 | 19-05-27 | |
David Lebwohl
CTO | Chief Tech/Sci/R&D Officer | 69 | 20-04-29 |
Li Lina
IRC | Investor Relations Contact | - | - |
- | - | ||
Aron Stein
LAW | General Counsel | - | - |
Derek Hicks
PRN | Corporate Officer/Principal | 51 | 21-12-19 |
Marika St Amand
HRO | Human Resources Officer | - | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Fred Cohen
BRD | Director/Board Member | 67 | 19-01-23 |
John Leonard
CEO | Chief Executive Officer | 66 | 14-06-30 |
Frank Verwiel
CHM | Chairman | 62 | 17-07-23 |
William Chase
BRD | Director/Board Member | 57 | 23-04-13 |
Jesse Goodman
BRD | Director/Board Member | 72 | 18-10-30 |
Georgia Keresty
BRD | Director/Board Member | 62 | 21-04-08 |
Muna Bhanji
BRD | Director/Board Member | 61 | 22-04-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 96,106,405 | 94,824,319 ( 98.67 %) | 0 | 98.67 % |
Company contact information
Intellia Therapeutics, Inc.
40 Erie Street Suite 130
02139, Cambridge
+857 285 6200
http://www.intelliatx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.29% | 2.11B | |
+3.33% | 42.11B | |
+48.83% | 40.08B | |
+8.66% | 40B | |
-10.82% | 26.87B | |
+8.15% | 24.58B | |
-23.59% | 18.44B | |
+1.72% | 11.94B | |
+33.08% | 11.66B | |
+6.96% | 11.01B |
- Stock Market
- Equities
- NTLA Stock
- Company Intellia Therapeutics, Inc.